Cargando…
Tocilizumab in COVID-19: Beware the risk of intestinal perforation
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V. and International Society of Chemotherapy.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204657/ https://www.ncbi.nlm.nih.gov/pubmed/32389721 http://dx.doi.org/10.1016/j.ijantimicag.2020.106009 |
| _version_ | 1783530090584342528 |
|---|---|
| author | Vikse, Jens Henry, Brandon Michael |
| author_facet | Vikse, Jens Henry, Brandon Michael |
| author_sort | Vikse, Jens |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7204657 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier B.V. and International Society of Chemotherapy. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72046572020-05-07 Tocilizumab in COVID-19: Beware the risk of intestinal perforation Vikse, Jens Henry, Brandon Michael Int J Antimicrob Agents Article Elsevier B.V. and International Society of Chemotherapy. 2020-07 2020-05-07 /pmc/articles/PMC7204657/ /pubmed/32389721 http://dx.doi.org/10.1016/j.ijantimicag.2020.106009 Text en © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Vikse, Jens Henry, Brandon Michael Tocilizumab in COVID-19: Beware the risk of intestinal perforation |
| title | Tocilizumab in COVID-19: Beware the risk of intestinal perforation |
| title_full | Tocilizumab in COVID-19: Beware the risk of intestinal perforation |
| title_fullStr | Tocilizumab in COVID-19: Beware the risk of intestinal perforation |
| title_full_unstemmed | Tocilizumab in COVID-19: Beware the risk of intestinal perforation |
| title_short | Tocilizumab in COVID-19: Beware the risk of intestinal perforation |
| title_sort | tocilizumab in covid-19: beware the risk of intestinal perforation |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204657/ https://www.ncbi.nlm.nih.gov/pubmed/32389721 http://dx.doi.org/10.1016/j.ijantimicag.2020.106009 |
| work_keys_str_mv | AT viksejens tocilizumabincovid19bewaretheriskofintestinalperforation AT henrybrandonmichael tocilizumabincovid19bewaretheriskofintestinalperforation |